Maggie Lynch of Outsourcing-Pharma reports on a new venture: ObvioHealth and its mobile clinical study platform designed to streamline patient recruitment, reporting, and post-marketing surveillance. See here for more information. ObvioHealth positions itself as “the next generation CRO.” They claim that their Claimit™ mobile study platform facilitates “100% site-less clinical trials and the opportunity for ‘hybrid’ studies where brick & mortar is a requirement.” Based in Singapore and Orlando Florida, the venture was launched in 2015; it recently raised its first investment round of $3 million from TKS I, a life science and healthcare focused venture fund. TKS I is made up of Tikehau Investment Management (Tikehau IM) and SPRIM’s VC Arm and SPRIM Ventures. Tikehau IM, based in France, is an asset management and investment group which manages over $17 billion of assets, while SPRIM is a global innovation firm focused on healthcare (early stage digital health investors).
The topic of “Site-less” trials is growing in frequency and interest. Although TrialSite News believes it is indeed difficult to have a completely site-less trial, we do believe that technologies such as ObioHealth’s Claimit, should they meet the business use case specifications, will help study sponsors become more efficient and potentially effective. For more information on current usage requirements see here for their Q&A link.